NEW YORK (GenomeWeb News) - ProNAi Therapeutics has secured $6.65 million in bridge funding from several financing sources, the company said today.
 
The Kalamazoo, Mich.-based startup uses DNA interference to develop drugs aimed at treating non-Hodgkin's lymphoma and prostate, breast, and colon cancers.
 
The company said it will use the funding to continue development of its lead drug candidate, PNT-100. ProNAi said it hopes to submit the compound to the FDA as an investigational new drug in mid-2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.